Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KOD

Kodiak Sciences Inc

Jul 26 • 04:00PM ET

3.25

Dollar change +0.03
Percentage change 0.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN SCHA FESM VTWO DFAT IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.44	Insider Own	7.44%	Shs Outstand	52.51M	Perf Week	13.24%
Market Cap	170.72M	Forward P/E	-	EPS next Y	-3.94	Insider Trans	-0.11%	Shs Float	48.63M	Perf Month	41.92%
Income	-232.75M	PEG	-	EPS next Q	-0.87	Inst Own	80.85%	Short Float	3.97%	Perf Quarter	2.04%
Sales	0.00M	P/S	-	EPS this Y	28.10%	Inst Trans	2.83%	Short Ratio	5.69	Perf Half Y	-32.43%
Book/sh	4.59	P/B	0.71	EPS next Y	-10.40%	ROA	-43.30%	Short Interest	1.93M	Perf Year	0.31%
Cash/sh	4.68	P/C	0.69	EPS next 5Y	12.40%	ROE	-73.45%	52W Range	1.37 - 7.77	Perf YTD	6.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.42%	ROI	-56.78%	52W High	-58.17%	Beta	2.32
Dividend TTM	-	Quick Ratio	10.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	137.23%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	10.12	EPS Y/Y TTM	24.88%	Oper. Margin	0.00%	RSI (14)	61.10	Volatility	7.61% 7.38%
Employees	111	Debt/Eq	0.74	Sales Y/Y TTM	-	Profit Margin	-	Recom	4.20	Target Price	3.00
Option/Short	Yes / Yes	LT Debt/Eq	0.70	EPS Q/Q	39.40%	Payout	-	Rel Volume	0.40	Prev Close	3.22
Sales Surprise	-	EPS Surprise	23.29%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	339.46K	Price	3.25
SMA20	18.96%	SMA50	12.42%	SMA200	-6.31%	Trades		Volume	136,063	Change	0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Resumed	Goldman	Sell	$2
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight	$7 → $12
Jul-27-23	Downgrade	UBS	Buy → Neutral	$15 → $4
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight	$7
Nov-15-22	Initiated	CapitalOne	Overweight	$24
Aug-02-22	Downgrade	Citigroup	Neutral → Sell	$6
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral	$90 → $21
Feb-11-22	Initiated	Goldman	Buy	$70
Feb-02-22	Upgrade	JP Morgan	Neutral → Overweight	$124 → $90
May-11-21	Upgrade	ROTH Capital	Neutral → Buy	$155 → $149
Mar-12-21	Initiated	Evercore ISI	Outperform
Mar-01-21	Downgrade	Barclays	Equal Weight → Underweight	$52 → $90
Feb-17-21	Downgrade	ROTH Capital	Buy → Neutral	$133 → $155
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform	$145 → $148
Dec-17-20	Initiated	Berenberg	Buy	$156
Dec-16-20	Initiated	UBS	Buy	$170
Dec-11-20	Initiated	Citigroup	Neutral	$134

Show Previous Ratings

Jul-10-24 12:00PM	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
Jun-20-24 08:23AM	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
Jun-14-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
May-29-24 04:36PM	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences (PR Newswire)
May-16-24 12:51PM	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
10:55PM	Loading…
May-15-24 10:55PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
May-14-24 07:31AM	Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug (Clinical Trials Arena)
May-13-24 07:32PM	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy (PR Newswire) +6.09%
May-02-24 04:30PM	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform (PR Newswire)
Apr-04-24 12:09PM	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks (Zacks)
Apr-01-24 05:04PM	Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript (Insider Monkey) -15.40%
12:00PM	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus (Zacks)
Mar-29-24 10:36AM	Q4 2023 Kodiak Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023 (InvestorPlace) -29.40%
08:32AM	Loading…
08:32AM	Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
06:30AM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-26-24 06:15AM	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 (PR Newswire) +16.01%
Jan-30-24 06:30AM	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting (PR Newswire) -8.58%
Jan-04-24 04:15PM	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:30AM	Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue? (Zacks) +6.21%
Nov-21-23 04:15PM	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -7.41% +6.67%
Nov-15-23 08:00AM	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates (Zacks) +5.21%
Nov-14-23 06:09PM	Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... (GuruFocus.com) +6.67%
04:01PM	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-06-23 05:00AM	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission (PR Newswire) -13.56%
Nov-01-23 11:21PM	KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING (PR Newswire) +6.21% +37.01%
Oct-17-23 01:44AM	Lonza Warns on 2024 Profitability Hit From Lost Moderna Revenue (The Wall Street Journal)
Oct-11-23 06:00AM	Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society (PR Newswire)
Sep-13-23 11:30AM	Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound? (Zacks)
06:00AM	Loading…
Sep-08-23 06:00AM	Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
Sep-07-23 06:00AM	New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion (PR Newswire)
Aug-16-23 10:26AM	Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus (Zacks)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals) -6.81% -9.97%
04:01PM	Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
08:34AM	Should You Buy Kodiak Sciences (KOD) Ahead of Earnings? (Zacks)
07:15AM	3 Biotech Stocks Poised to Beat Q2 Earnings Estimates (Zacks)
Aug-02-23 10:09AM	Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards? (Zacks) +5.33%
Jul-27-23 02:30AM	4 big analyst cuts: Carvana 'well above our increased target,' says Morgan Stanley (Investing.com) -10.49%
Jul-26-23 06:42AM	Kodiak Sciences Inc. (NASDAQ:KOD) Is Expected To Breakeven In The Near Future (Simply Wall St.) -10.74%
Jul-25-23 09:16AM	Kodiak (KOD) Down as Late-Stage DME Studies Fail (Zacks) -7.98%
Jul-24-23 06:26AM	CORRECTED-UPDATE 1-Kodiak Sciences scraps development of eye disorder drug (Reuters) -45.88%
06:09AM	Kodiak Sciences scraps development of eye disorder drug (Reuters)
06:00AM	Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program (PR Newswire)
Jun-14-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report? (Zacks)
May-30-23 04:15PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
11:14AM	Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition (Zacks)
May-16-23 07:44AM	Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) +10.44%
May-15-23 04:01PM	Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) +12.61%
Apr-27-23 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report? (Zacks)
Apr-21-23 07:30AM	Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting (PR Newswire)
Apr-11-23 06:29AM	We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate (Simply Wall St.)
Apr-04-23 01:16PM	Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study (Zacks) -8.56%
Apr-03-23 11:38AM	Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why (Zacks) -12.34%
07:30AM	Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases (PR Newswire)
Mar-28-23 04:08PM	Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (PR Newswire) +23.27%
Mar-01-23 05:55AM	In the wake of Kodiak Sciences Inc.'s (NASDAQ:KOD) latest US$39m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Feb-09-23 07:30AM	Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting (PR Newswire)
Jan-04-23 07:00AM	Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +9.40%
Dec-09-22 11:30AM	Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-30-22 09:55AM	Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect? (Zacks)
Nov-16-22 04:30PM	Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
Nov-14-22 09:55AM	Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High? (Zacks)
Nov-10-22 02:17PM	Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus (Zacks) +5.79%
Nov-09-22 04:01PM	Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
Nov-02-22 06:24AM	We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-22-22 06:06AM	Owning 44% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD), (Simply Wall St.)
Sep-08-22 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report? (Zacks)
Sep-07-22 04:05PM	Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference (PR Newswire)
Aug-26-22 01:34PM	Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why (Zacks)
Aug-19-22 12:32PM	Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab (Zacks) -8.17%
Aug-18-22 05:47PM	Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO) (PR Newswire)
Aug-10-22 10:57AM	Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus (Zacks) +14.47%
Aug-09-22 04:33PM	Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
Aug-08-22 08:39AM	Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains (Benzinga) +14.07%
06:30AM	Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion (PR Newswire)
Aug-05-22 04:30PM	Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy (PR Newswire) +6.33%
Aug-02-22 12:07PM	Why Kodiak Sciences Stock Is Sharply Lower Today (Motley Fool) -12.98%
Jun-12-22 09:00AM	Five Beaten-Up Biotech Stocks Saw Big Share Purchases (Barrons.com)
Jun-09-22 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report? (Zacks) -10.23%
10:32AM	Even if stocks break out, the overwhelming trend is down (MarketWatch)
May-27-22 08:00AM	Kodiak Sciences to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-19-22 08:00AM	Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases (PR Newswire) +11.83%
May-13-22 01:44PM	Stock rebound uncertain for U.S. biotechs as risks multiply for investors (American City Business Journals)
May-11-22 12:38PM	Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus (Zacks) -7.61%
11:14AM	Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:10PM	Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
May-06-22 08:50AM	Should You Buy Kodiak (KOD) Ahead of Earnings? (Zacks)
Apr-29-22 05:30AM	Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences (PR Newswire)
Mar-31-22 11:30AM	Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report? (Zacks)
Mar-23-22 06:32PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Mar-05-22 11:07AM	2 Dirt Cheap Biotechs to Buy If You're a Contrarian (Motley Fool)
Mar-04-22 05:10AM	The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals (Zacks) -10.98%
Mar-03-22 06:21PM	Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More (Zacks)
10:59AM	Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why (Zacks)
Mar-02-22 10:11AM	Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus (Zacks)
08:36AM	Why Kodiak Sciences (KOD) Might Surprise This Earnings Season (Zacks)
Mar-01-22 04:05PM	Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (PR Newswire)
Feb-25-22 10:00AM	Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks (Zacks)
Feb-23-22 06:00PM	Peninsula biotech stock loses 80% after eye drug's late-stage study fails (American City Business Journals) -80.42% -7.00%

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BORGESON JOHN A.	See Remarks	Jun 17 '24	Sale	2.75	2,874	7,904	182,164	Jun 18 05:00 PM
BORGESON JOHN A.	See Remarks	Jun 12 '24	Sale	2.92	1,558	4,549	179,544	Jun 13 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KOD

Kodiak Sciences Inc

Upgrade your FINVIZ experience